Gemcitabine or Gemcitabine Plus Docetaxel After Cisplatin, Etoposide and Radiation in Non Small Cell Lung Cancer (NSCLC)

A Randomized Study of Gemcitabine Plus Docetaxel After Cisplatin, Etoposide and Radiation Therapy in Stage III Unresectable NSCLC

To assess the 2 year survival of patients with Stage III unresectable non-small cell lung cancer receiving consolidation gemcitabine or gemcitabine plus docetaxel following concurrent chemotherapy and radiation.

Inclusion Criteria:

• histologic or cytologic proof of single primary non-small cell lung cancer
• No prior chemotherapy or radiation therapy
• no prior malignancy

Exclusion Criteria:

• pregnancy or breastfeeding
• serious concomitant systemic disorder
• unintentional weight loss greater than 10%